Melagatran

CAS : 159776-70-2

Ref. 3D-FM25041

Informations sur le produit

• Nom: Melagatran
• Synonymes: N-[(1R)-2-[(2S)-2-[[[[4-(Aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]glycineH-319/68, Glycine, N-[(1R)-2-[(2S)-2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-, Glycine, N-[2-[2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-, [S-(R*,S*)]-, H-319/68, N-[(1R)-2-[(2S)-2-[[[[4-(Aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]glycine, N-[(1R)-2-{(2S)-2-[(4-carbamimidoylbenzyl)carbamoyl]azetidin-1-yl}-1-cyclohexyl-2-oxoethyl]glycine
• CAS: 159776-70-2

Description

Melagatran is a coumarin derivative that acts as a thrombin receptor antagonist. It has been shown to have anti-thrombotic effects in an experimental model of balloon injury and in a vivo model of arterial thrombosis. Melagatran has been shown to significantly inhibit the progression of atherosclerotic lesions when administered orally, without adverse effects on blood coagulation or liver function. This drug may be useful for the prevention or treatment of cardiovascular disease in patients with hepatic impairment. Melagatran is rapidly converted into melagatran in vivo and has no significant pharmacological activity. The drug can be detected by analytical methods such as high performance liquid chromatography (HPLC).

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 429.51 g/mol
• Formule: C₂₂H₃₁N₅O₄
• Degré de pureté: Min. 95%
• Couleur/Forme: White Powder